Efficacy and safety of nivolumab plus ipilimumab in gastrointestinal cancers: a systematic review and meta-analysis

Efficacy and safety of nivolumab plus ipilimumab in gastrointestinal cancers: a systematic review and meta-analysis

IntroductionGastrointestinal (GI) cancers represent a significant global health burden, and the need for more effective treatment options is exceptionally pressing. The present meta-analysis aimed to explore the efficacy and safety of the combination of nivolumab and ipilimumab in treating GI cancer...

Full description

Saved in:

Bibliographic Details
Main Authors:	Bowen Dai, Jiaping Jiang, Xiaoyu Yu, Haihua Zhan, Zhengchuan Hu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Oncology
Subjects:	nivolumab ipilimumab gastrointestinal cancer objective response rate efficacy meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1515992/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma
by: Valerie Glutsch, et al.
Published: (2024-12-01)

Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan
by: Tomoki Taniguchi, et al.
Published: (2024-12-01)

Neoadjuvant immunotherapy with ipilimumab/nivolumab induces a complete response of a primary malignant melanoma in an 89 years old patient
by: Pascal Spahn, et al.
Published: (2024-12-01)

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment
by: Sabine Schmid, MD, et al.
Published: (2024-12-01)

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
by: Satoshi Endo, et al.
Published: (2025-01-01)

Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study
by: Yoshihiko Tasaki, et al.
Published: (2025-01-01)

Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in Poland
by: Renata Pacholczak-Madej, et al.
Published: (2024-11-01)

Cytokine release syndrome treated with tocilizumab following ipilimumab–nivolumab combination therapy in advanced renal cell carcinoma
by: Toru Inoue, et al.
Published: (2025-01-01)

Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma
by: Maki Todo, et al.
Published: (2025-02-01)

Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
by: Ella Xiaoyan Du, et al.
Published: (2024-08-01)

Durable Clinical Benefit after Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer
by: Yat-Fung Chow, et al.
Published: (2023-10-01)

The burden and clinical trajectory of immune checkpoint inhibitor-induced endocrinopathies: an 8-year experience
by: Fateen Ata, et al.
Published: (2024-12-01)

Case report: A severe myositis mimicking bulbar palsy after administration of immune checkpoint inhibitors
by: Philippe Rochigneux, et al.
Published: (2025-02-01)

Bullous pemphigoid associated with the use of nivolumab in a patient with metastatic melanoma: a case report.
by: Diego Lopes Paim Miranda, et al.
Published: (2020-01-01)

Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival
by: Ragnhild Reehorst Lereim, et al.
Published: (2025-12-01)

Nivolumab Efficacy and Safety in Cancer Patients with Renal Dysfunction
by: Ezgi Degerli, et al.
Published: (2024-09-01)

Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients
by: Elena Poddubskaya, et al.
Published: (2024-12-01)

MODERN TREATMENT OF METASTATIC MELANOMA: FROM STANDARDS TO AN INDIVIDUALIZED APPROACH IN REAL CLINICAL PRACTICE
by: N. V. Zhukova, et al.
Published: (2018-06-01)

Immunotherapy‐Induced Type 1 Diabetes Mellitus Causing Diabetic Ketoacidosis: A Case Report and Review of Current Guidelines
by: Patrick Disterhaft, et al.
Published: (2024-11-01)

Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression‐free survival based on reconstructed individual patient data
by: Andrea Ossato, et al.
Published: (2023-02-01)

Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
by: Amparo Burgos-San José, et al.
Published: (2021-05-01)

Stereotactic Radiotherapy Plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1/2 Clinical CA209-9KH Trial
by: Milan Vošmik, et al.
Published: (2024-10-01)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
by: Wolfram Samlowski, et al.
Published: (2023-02-01)

Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas
by: Santosh Kesari, et al.
Published: (2024-12-01)

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
by: Arun Singh, et al.
Published: (2020-05-01)

Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma
by: D. König, et al.
Published: (2024-12-01)

Multifocal disseminated necrotizing leukoencephalopathy as severe central nervous system toxicity from nivolumab therapy for Hodgkin lymphoma: a case report
by: Hussein Algahtani, et al.
Published: (2025-01-01)

A case of eruptive keratoacanthomas and lichen planus secondary to nivolumab treatment for stage IV melanoma
by: Daniel S. Alicea, MS, et al.
Published: (2025-03-01)

Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab
by: Jiajia Chen, et al.
Published: (2025-12-01)

Correction: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Published: (2020-10-01)

Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE)
by: Hidekazu Hirano, et al.
Published: (2025-02-01)

Understanding and overcoming resistance to immunotherapy in genitourinary cancers
by: Sean T Evans, et al.
Published: (2024-12-01)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
by: Margaux Geier, et al.
Published: (2020-10-01)

Efficacy and safety of remimazolam besylate and ciprofol in painless gastrointestinal endoscopy in the elderly
by: Ziwei Zhu
Published: (2024-12-01)

Nationwide multi-centric prospective study for the identification of biomarkers to predict the treatment responses of nivolumab through comprehensive analyses of pretreatment plasma exosome mRNAs from head and neck cancer patients (BIONEXT study)
by: Kuniaki Sato, et al.
Published: (2025-01-01)

First-line Nivolumab plus Ipilimumab in patients with advanced melanoma previously treated with adjuvant systemic therapy
by: K. Kisielewska, et al.
Published: (2024-01-01)

5-Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan as a Potential Standard for Second-line Therapy in Extrapulmonary Neuroendocrine Carcinomas
by: I-Wei Ho, et al.
Published: (2024-12-01)

CRH-YOLO for precise and efficient detection of gastrointestinal polyps
by: Jingjing Wan, et al.
Published: (2024-12-01)

Retinal Toxicity after Initial Administration of Nivolumab and Ipilimumab
by: Adnan Kilani, et al.
Published: (2023-01-01)

Neoadjuvant ipilimumab plus nivolumab in locally advanced melanoma: A real-world single-centre retrospective study
by: Patrick Schummer, et al.
Published: (2023-01-01)